Back to top

Image: Bigstock

GlaxoSmithKline (GSK) Stock Sinks As Market Gains: What You Should Know

Read MoreHide Full Article

GlaxoSmithKline (GSK - Free Report) closed the most recent trading day at $35.55, moving -0.14% from the previous trading session. This change lagged the S&P 500's 1.04% gain on the day. Elsewhere, the Dow gained 0.58%, while the tech-heavy Nasdaq added 2.52%.

Prior to today's trading, shares of the drug developer had gained 0.17% over the past month. This has outpaced the Medical sector's loss of 5.72% and the S&P 500's loss of 0.15% in that time.

Investors will be hoping for strength from GSK as it approaches its next earnings release. The company is expected to report EPS of $0.69, down 28.87% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $10.89 billion, down 6.43% from the year-ago period.

For the full year, our Zacks Consensus Estimates are projecting earnings of $2.78 per share and revenue of $45.95 billion, which would represent changes of -6.71% and +4.87%, respectively, from the prior year.

Investors might also notice recent changes to analyst estimates for GSK. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 7.18% lower. GSK currently has a Zacks Rank of #5 (Strong Sell).

Digging into valuation, GSK currently has a Forward P/E ratio of 12.81. This represents a discount compared to its industry's average Forward P/E of 12.94.

It is also worth noting that GSK currently has a PEG ratio of 3.29. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. GSK's industry had an average PEG ratio of 1.9 as of yesterday's close.

The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 216, which puts it in the bottom 16% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


GSK PLC Sponsored ADR (GSK) - free report >>

Published in